as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹120.38
Change
+3.78 (3.24%)
Open
₹117.3
Prev. Close
₹116.6
Day High
₹121.0
Day Low
₹117.0
Volume Analysis
Traded
8,996,779
Delivered
2,633,247
Delivery %
29.27%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (3)
- •Low return on equity (5.33%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (49/100)
Opportunities (1)
- •Strong 3-year EPS growth (31.6%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹125.92 | ₹123.46 | ₹121.92 | ₹119.46 | ₹117.92 | ₹115.46 | ₹113.92 |
| Fibonacci | ₹123.46 | ₹121.93 | ₹120.99 | ₹119.46 | ₹117.93 | ₹116.99 | ₹115.46 |
| Camarilla | ₹121.48 | ₹121.11 | ₹120.75 | ₹119.46 | ₹120.01 | ₹119.65 | ₹119.28 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+192.82%
1 Week
-1.61%
1 Month
+13.36%
3 Months
+103.62%
6 Months
+223.6%
1 Year
+146.33%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹29.79
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
10.42%
Net margin 7.23% × asset turnover 0.93x × equity multiplier 1.55x
Company Overview
Sector
Healthcare
Market Cap
₹6,596 Cr
P/E (TTM)
56.2
ROE
5.33%
Book Value
₹22.8
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Morepen Lab. Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Financial Strength (100/100), while Cash Flow (12/100) is the weakest area to weigh before deciding. Notably: Low return on equity (5.33%); promoter holding is falling. Strong 3-year EPS growth (31.6%).
TopFund Score — Fundamentals Quality
49/100 — WeakData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 5.29 times its book value
- −The company has delivered a poor sales growth of 8.73% over past five years.
- −Company has a low return on equity of 9.26% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
CRISIL assigned Morepen Laboratories an ESG rating of 60, indicating 'Adequate', for FY2026.
First phase capacity expansion completed ahead of schedule; reactor capacity rises from 535 KL to 614 KL.
Newspaper publication for completion of dispatch of the notice of 41st AGM and Annual report for the FY 2025-26
Morepen Laboratories’ 41st AGM on 26 Sep 2026; proposed ₹0.20 final dividend, record date 19 Sep 2026.
Morepen Laboratories filed its FY2025-26 BRSR as part of the annual report.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 401 | 422 | 445 | 423 | 455 | 438 | 453 | 466 | 425 | 412 | 484 | 485 | 570 |
| Expenses + | 375 | 388 | 394 | 375 | 404 | 394 | 417 | 424 | 401 | 381 | 438 | 460 | 488 |
| Operating Profit | 26 | 34 | 51 | 48 | 52 | 44 | 36 | 42 | 24 | 31 | 46 | 24 | 83 |
| OPM % | 7.0% | 8.0% | 11.0% | 11.0% | 11.0% | 10.0% | 8.0% | 9.0% | 6.0% | 7.0% | 10.0% | 5.0% | 14.0% |
| Other Income + | 2 | 3 | 4 | 4 | 3 | 5 | 5 | 5 | 4 | 30 | 4 | 8 | 5 |
| Interest | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 5 | 4 | 4 | 4 | 4 | 5 |
| Depreciation | 8 | 8 | 8 | 10 | 6 | 2 | 5 | 16 | 9 | 11 | 10 | 6 | 8 |
| Profit before tax | 21 | 29 | 44 | 42 | 48 | 46 | 35 | 26 | 16 | 46 | 35 | 23 | 75 |
| Tax % | 29.0% | 26.0% | 27.0% | 32.0% | 25.0% | 24.0% | 24.0% | 21.0% | 26.0% | 10.0% | 22.0% | 33.0% | 24.0% |
| Net Profit + | 15 | 21 | 32 | 29 | 36 | 35 | 27 | 20 | 11 | 41 | 28 | 16 | 56 |
| EPS in Rs | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 401 | 485 | 595 | 607 | 769 | 853 | 1,188 | 1,547 | 1,418 | 1,690 | 1,812 | 1,806 | 1,951 |
| Expenses + | 352 | 424 | 534 | 542 | 701 | 785 | 1,070 | 1,410 | 1,338 | 1,532 | 1,638 | 1,680 | 1,767 |
| Operating Profit | 48 | 62 | 61 | 65 | 68 | 69 | 119 | 137 | 80 | 159 | 174 | 126 | 184 |
| OPM % | 12.0% | 13.0% | 10.0% | 11.0% | 9.0% | 8.0% | 10.0% | 9.0% | 6.0% | 9.0% | 10.0% | 7.0% | 9.0% |
| Other Income + | 1 | -3 | 4 | 4 | 4 | 9 | 12 | 10 | 6 | 14 | 18 | 47 | 48 |
| Interest | 9 | 10 | 8 | 4 | 2 | 2 | 2 | -7 | 2 | 4 | 8 | 16 | 17 |
| Depreciation | 39 | 35 | 34 | 34 | 40 | 37 | 30 | 28 | 28 | 33 | 29 | 36 | 36 |
| Profit before tax | 2 | 13 | 24 | 30 | 29 | 39 | 99 | 127 | 56 | 135 | 155 | 120 | 179 |
| Tax % | 6.0% | -1.0% | 0.0% | 0.0% | 1.0% | 14.0% | 1.0% | 20.0% | 31.0% | 29.0% | 24.0% | 20.0% | — |
| Net Profit + | 2 | 13 | 24 | 30 | 29 | 34 | 97 | 102 | 39 | 97 | 118 | 96 | 141 |
| EPS in Rs | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 2 | 2 | 3 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 9.0% | 12.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 78 | 91 | 106 | 136 | 163 | 194 | 335 | 483 | 651 | 745 | 1,047 | 1,137 |
| Borrowings + | 201 | 187 | 169 | 134 | 132 | 133 | 17 | 19 | 25 | 29 | 105 | 208 |
| Other Liabilities + | 121 | 156 | 173 | 226 | 230 | 246 | 416 | 473 | 332 | 417 | 517 | 482 |
| Total Liabilities | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,293 | 1,778 | 1,936 |
| Fixed Assets + | 322 | 297 | 272 | 264 | 236 | 216 | 225 | 252 | 267 | 307 | 489 | 513 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 14 | 17 | 24 | 28 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 85 | 124 |
| Other Assets + | 167 | 227 | 266 | 321 | 379 | 446 | 631 | 804 | 827 | 960 | 1,176 | 1,277 |
| Total Assets | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,293 | 1,778 | 1,936 |
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 96 | 102 | 102 | 110 | 110 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 51 | 50 | 41 | 63 | 17 | 11 | 51 | -60 | -91 | 73 | 32 | 33 |
| Cash from Investing Activity + | -32 | -27 | -14 | -27 | -13 | -12 | -70 | -32 | -47 | -83 | -322 | -126 |
| Cash from Financing Activity + | -19 | -27 | -24 | -38 | 0 | 5 | 47 | 66 | 144 | 5 | 300 | 97 |
| Net Cash Flow | 0 | -4 | 3 | -1 | 4 | 4 | 28 | -26 | 6 | -5 | 10 | 4 |
| CFO/OP | 105 | 81 | 66 | 98 | 26 | 25 | 44 | -26 | -94 | 70 | 40 | 46 |
| Free Cash Flow | 46 | 41 | 31 | 37 | 6 | -6 | 10 | -127 | -137 | -8 | -182 | -127 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 58.2% | 57.46% | 57.76% | 57.96% | 60.57% | 60.46% | 60.72% | 61.09% | 61.22% | 61.46% | 61.5% | 61.59% |
| Promoters | 38.22% | 38.22% | 38.22% | 38.22% | 35.66% | 35.66% | 35.66% | 35.66% | 35.66% | 35.66% | 35.66% | 35.66% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| FII | 1.29% | 2.11% | 1.85% | 1.67% | 2.08% | 2.22% | 1.94% | 1.72% | 1.62% | 1.62% | 1.59% | 1.46% |
| DII | 2.27% | 2.21% | 2.15% | 2.14% | 1.69% | 1.64% | 1.67% | 1.5% | 1.49% | 1.25% | 1.25% | 1.28% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Morepen Lab. Ltd (this stock) | 6,596 | 56.2 | 5.26 | 5.33% |
| Kovai Medical Center & Ho | 6,653 | 115.0 | 23.07 | 22.2% |
| Symbiotec Pharmalab Ltd | 6,447 | 64.8 | — | 11.7% |
| Sun Pharma Adv.res.co.ltd | 6,784 | 4.25 | 5.06 | 279.0% |
| Orchid Pharma Limited | 6,377 | 353.0 | 3.55 | 1.49% |
| Senores Pharmaceuticals L | 6,241 | 49.4 | 6.67 | 13.4% |
| Nephrocare Health Serv L | 7,005 | 82.3 | 6.28 | 8.83% |
Which Mutual Funds Hold Morepen Lab. Ltd?
Frequently Asked Questions about Morepen Lab. Ltd
Morepen Lab. Ltd (MOREPENLAB) closed at ₹120.38 on NSE on 25 September 2026, up 3.78 (3.24%) from the previous close.
Morepen Lab. Ltd trades on the NSE (National Stock Exchange of India) under the symbol MOREPENLAB.
Morepen Lab. Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 56.2.
Morepen Lab. Ltd has a dividend yield of 0.17%.
Morepen Lab. Ltd's 52-week high is ₹127.0 and its 52-week low is ₹33.0.
Morepen Lab. Ltd has a market capitalisation of ₹6,596 crore.
Morepen Lab. Ltd has a TopFund Quality Score of 49/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Morepen Lab. Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.